Back to Search
THOMAS POLASCIK, M.D.
M.D.
Urology Physician
NPI: 1083798979IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
98-01017(NC)
CMS Specialties
PrimaryUROLOGY
Education
UNIVERSITY OF CHICAGO, PRITZKER SCHOOL OF MEDICINE
Class of 1991
Research & Publications (20)
Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
PMID 19288576·Cancer·2009
8-other
Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients.
PMID 19660791·Urology·2009
8-other
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
PMID 18543281·Prostate·2008
4-observational
Zoledronic acid in the management of metastatic bone disease.
PMID 18728715·Ther Clin Risk Manag·2008
8-other
Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
PMID 17923854·Prostate Cancer Prostatic Dis·2008
6-review
From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer.
PMID 18709901·Oncology (Williston Park)·2008
6-review
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
PMID 17656220·Urology·2007
8-other
Short Term Clinical Outcome after Laparoscopic Cryoablation of the Renal Tumor < or = 3.5 cm.
PMID 17994792·Technol Cancer Res Treat·2007
8-other
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
PMID 16286123·Urology·2005
3-trial
Molecular genetics and histopathologic features of adult distal nephron tumors.
PMID 12475646·Urology·2002
6-review
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy.
PMID 19583717·BJU Int·2010
6-review
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.
PMID 19616835·Urology·2009
4-observational
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
PMID 19628263·Urology·2009
8-other
Factors predicting prostatic biopsy Gleason sum under grading.
PMID 19447436·J Urol·2009
4-observational
Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy.
PMID 19448228·Anesth Analg·2009
2-rct
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
PMID 19501891·Urology·2009
8-other
Pathologic basis of focal therapy for early-stage prostate cancer.
PMID 19352395·Nat Rev Urol·2009
6-review
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
PMID 19616259·J Urol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- DUKE CANCER CENTER 5-1 UROLOGY, DUKE CANCER CENTER, DUKE UNIVERSITY MEDICAL CENTER
DURHAM, NC 27710 - Phone
- (919) 684-4946
Quick Facts
- NPI
- 1083798979
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile